Strs Ohio Increases Stock Holdings in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)

Strs Ohio raised its stake in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CEREGet Rating) by 143.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,900 shares of the biotechnology company’s stock after purchasing an additional 2,300 shares during the period. Strs Ohio’s holdings in Cerevel Therapeutics were worth $110,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. High Net Worth Advisory Group LLC purchased a new position in shares of Cerevel Therapeutics during the third quarter worth approximately $28,000. Nisa Investment Advisors LLC grew its position in shares of Cerevel Therapeutics by 46.8% during the second quarter. Nisa Investment Advisors LLC now owns 1,380 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 440 shares during the last quarter. Centaurus Financial Inc. purchased a new position in shares of Cerevel Therapeutics during the first quarter worth approximately $105,000. Amundi purchased a new position in shares of Cerevel Therapeutics during the second quarter worth approximately $190,000. Finally, Sei Investments Co. purchased a new position in shares of Cerevel Therapeutics during the second quarter worth approximately $294,000.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on CERE. Cantor Fitzgerald raised their target price on shares of Cerevel Therapeutics from $41.00 to $46.00 in a research report on Tuesday, December 20th. Loop Capital initiated coverage on Cerevel Therapeutics in a report on Tuesday, November 1st. They set a “buy” rating and a $40.00 price target for the company. Bank of America initiated coverage on Cerevel Therapeutics in a report on Thursday, October 20th. They set a “buy” rating and a $39.00 price target for the company. JPMorgan Chase & Co. decreased their price target on Cerevel Therapeutics from $49.00 to $40.00 and set an “overweight” rating for the company in a report on Tuesday, December 6th. Finally, HC Wainwright decreased their price target on Cerevel Therapeutics from $50.00 to $48.00 and set a “buy” rating for the company in a report on Wednesday, November 9th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Cerevel Therapeutics has an average rating of “Moderate Buy” and an average price target of $39.67.

Cerevel Therapeutics Price Performance

Cerevel Therapeutics stock opened at $32.84 on Friday. Cerevel Therapeutics Holdings, Inc. has a one year low of $19.86 and a one year high of $41.46. The company has a debt-to-equity ratio of 0.56, a quick ratio of 16.64 and a current ratio of 16.64. The business has a fifty day moving average of $29.71 and a two-hundred day moving average of $29.32. The company has a market cap of $5.13 billion, a P/E ratio of -15.42 and a beta of 1.47.

Cerevel Therapeutics (NASDAQ:CEREGet Rating) last released its earnings results on Tuesday, November 8th. The biotechnology company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.04). As a group, analysts predict that Cerevel Therapeutics Holdings, Inc. will post -2.36 earnings per share for the current fiscal year.

Insider Transactions at Cerevel Therapeutics

In other news, CEO N Anthony Coles sold 50,000 shares of Cerevel Therapeutics stock in a transaction on Thursday, January 5th. The stock was sold at an average price of $29.94, for a total transaction of $1,497,000.00. Following the completion of the transaction, the chief executive officer now owns 2,704 shares of the company’s stock, valued at approximately $80,957.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.30% of the company’s stock.

About Cerevel Therapeutics

(Get Rating)

Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety.

Recommended Stories

Want to see what other hedge funds are holding CERE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cerevel Therapeutics Holdings, Inc. (NASDAQ:CEREGet Rating).

Institutional Ownership by Quarter for Cerevel Therapeutics (NASDAQ:CERE)

Receive News & Ratings for Cerevel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerevel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.